Dr. Elias Thorne, MD, PhD

There are neurologists who study pain. Then there are those who have made the molecular architecture of suffering their life's work. Dr. Elias Thorne belongs to the second group — and his two decades at NNPRC have produced a body of research that has meaningfully shaped how clinicians approach gabapentinoid prescribing in North America.

Education & Training

Dr. Thorne completed his undergraduate studies in biochemistry at the University of Michigan (summa cum laude, 1989), before entering the MD-PhD program at Johns Hopkins University School of Medicine. His doctoral thesis, completed under the mentorship of Dr. Solomon Snyder's research group, examined the pharmacology of amino acid neurotransmitter transport systems — work that proved remarkably prescient when gabapentin's dependency on the large neutral amino acid (LNAA) transporter for intestinal absorption was later characterized. He received his MD and PhD degrees concurrently in 1997.

His neurology residency at Massachusetts General Hospital was followed by a two-year subspecialty fellowship in Pain Medicine at the UCSF Pain Management Center, where he trained under leading experts in spinal cord stimulation, intrathecal drug delivery, and the then-emerging science of central sensitization. He joined NNPRC in 2001 as a Senior Research Fellow and was appointed Lead Researcher and Director of Translational Research in 2003.

Research Focus & Scholarly Contributions

Dr. Thorne's primary research domain is the intersection of voltage-gated calcium channel pharmacology and clinical neuropathic pain management. His laboratory work has focused predominantly on the α2δ subunit family — specifically α2δ-1 and α2δ-2 — characterizing their expression patterns following peripheral nerve injury, their role in central sensitization, and the binding kinetics of gabapentinoids at each subtype. This mechanistic work underlies much of NNPRC's clinical research program.

He has authored or co-authored 94 peer-reviewed publications in journals including Neuron, Pain, Journal of Pharmacology and Experimental Therapeutics, Neuropharmacology, and the New England Journal of Medicine. His 2009 paper in Pain on inter-patient variability in gabapentin bioavailability — attributing observed variance to polymorphisms in the SLC7A5 gene encoding the LNAA transporter — has been cited over 1,400 times and directly informed updated prescribing guidance from the American Academy of Neurology.

A 2016 collaborative study with UCSF and Stanford Pain Centers, of which Dr. Thorne was principal investigator, examined long-term outcomes in 2,800 patients with diabetic peripheral neuropathy managed on gabapentinoid therapy across a five-year follow-up period. The study's finding — that structured dose titration guided by CrCl monitoring reduced serious adverse events by 34% compared to standard practice — became a cornerstone of NNPRC's clinical protocol recommendations and was incorporated into the 2019 AAN practice guideline update.

Selected Publications

Clinical Practice & Advisory Roles

Dr. Thorne maintains an active, though limited, clinical practice at the NNPRC Ambulatory Neurology Clinic in San Diego, where he evaluates complex neuropathic pain cases referred from across the Western United States. He is a Consulting Neurologist to the VA San Diego Healthcare System's Pain Management Program and serves on the Clinical Pharmacology advisory committee for the California Medical Board.

At the national level, he is a member of the American Academy of Neurology Quality Measures Subcommittee, contributing to the development of performance metrics for neuropathic pain management. He has testified before the Senate HELP Committee on gabapentin prescribing trends and the challenge of balancing legitimate pain management access against emerging misuse patterns — a tension he characterizes as "the defining prescribing challenge of the current decade."

Teaching & Mentorship

More than 40 clinical fellows have completed research rotations in Dr. Thorne's laboratory since 2003. He is a Clinical Professor of Neurology (adjunct) at UC San Diego School of Medicine and delivers the annual Roger C. Duvoisin Lecture in Neuropharmacology — a distinction established in 2018. His mentorship philosophy is direct: he expects fellows to generate a hypothesis within 60 days of arrival and to be first author on at least one submitted manuscript before completing their rotation.

Outside the laboratory, he is an occasional contributor to Neurology Today and maintains a professional presence at annual meetings of the Society for Neuroscience, the American Pain Society, and the International Association for the Study of Pain. He is not on social media. He prefers it that way.